Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Ernst Robert Lengyel

TitleProfessor
InstitutionUniversity of Chicago
DepartmentBSD Academic Admin
AddressChicago IL 60637
Email
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    I trained both as a scientist and as a physician and, throughout my career, I have focused on the treatment and biology of ovarian cancer (OvCa). My Ph.D. thesis was on the role of proteases in ovarian cancer and my clinical fellowship involved a special emphasis on the treatment of patients with this disease. As a surgeon and clinician, I am familiar with the presentation of ovarian cancer in patients, and experience the incredible obstacles we face in its treatment. In the laboratory, I have built the research infrastructure necessary for effective ovarian cancer research.
    The Lengyel lab has elucidated, at least in part, the first critical steps of ovarian cancer metastasis by paying close attention to the host microenvironment. We have collected the 25 most commonly used ovarian cancer cell lines from all over the world, including those which are chemotherapy resistant. We have established several mouse models for OvCa, and using a genetic mouse model (K-rasG12D/+/Pten-/- -- established by Dr. Tyler Jacks), a syngeneic orthotopic mouse model using mouse OvCa cells (ID8 -- established by K. Roby), and several xenograft ip models using primary and cultured human OvCa cells. I have also established a prospective OvCa tissue bank and, together with 2 gynecologic pathologists, we have assembled 13 tissue arrays including normal tissue, borderline tumor and primary tumor, & corresponding metastasis. As a surgeon, the main focus of my practice is patients with OvCa; therefore, I will be able to enroll a substantial number of patients on the proposed clinical trial and have the infrastructure in place to collect the tissue required for the translational studies.
    My clinical experience treating ovarian cancer, together with my laboratory, which focuses on OvCa biology, gives me a unique opportunity and obligation to find new treatments that can benefit patients with ovarian cancer.


    Collapse Biography 
    Collapse education and training
    University of Munich, MunichM.D.06/1992M.D.

    Collapse ORNG Applications 
    Collapse Websites

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Ko SY, Lee W, Kenny HA, Dang LH, Ellis LM, Jonasch E, Lengyel E, Naora H. Cancer-derived small extracellular vesicles promote angiogenesis by heparin-bound, bevacizumab-insensitive VEGF, independent of vesicle uptake. Commun Biol. 2019; 2:386. PMID: 31646189.
      View in: PubMed
    2. Li G, Eckert MA, Chang JW, Montgomery JE, Chryplewicz A, Lengyel E, Moellering RE. Ultrasensitive, multiplexed chemoproteomic profiling with soluble activity-dependent proximity ligation. Proc Natl Acad Sci U S A. 2019 Oct 22; 116(43):21493-21500. PMID: 31591248.
      View in: PubMed
    3. Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, Brimacombe KR, Marugan J, Ferrer M, Lengyel E. Quantitative high-throughput screening using an organotypic model identifies compounds that inhibit ovarian cancer metastasis. Mol Cancer Ther. 2019 Sep 27. PMID: 31562255.
      View in: PubMed
    4. Dauer P, Lengyel E. New Roles for Glycogen in Tumor Progression. Trends Cancer. 2019 Jul; 5(7):396-399. PMID: 31311654.
      View in: PubMed
    5. Eckert MA, Coscia F, Chryplewicz A, Chang JW, Hernandez KM, Pan S, Tienda SM, Nahotko DA, Li G, Blaženovic I, Lastra RR, Curtis M, Yamada SD, Perets R, McGregor SM, Andrade J, Fiehn O, Moellering RE, Mann M, Lengyel E. Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature. 2019 05; 569(7758):723-728. PMID: 31043742.
      View in: PubMed
    6. Chryplewicz A, Tienda SM, Nahotko DA, Peters PN, Lengyel E, Eckert MA. Mutant p53 regulates LPA signaling through lysophosphatidic acid phosphatase type 6. Sci Rep. 2019 Mar 26; 9(1):5195. PMID: 30914657.
      View in: PubMed
    7. Bast RC, Matulonis UA, Sood AK, Ahmed AA, Amobi AE, Balkwill FR, Wielgos-Bonvallet M, Bowtell DDL, Brenton JD, Brugge JS, Coleman RL, Draetta GF, Doberstein K, Drapkin RI, Eckert MA, Edwards RP, Elias KM, Ennis D, Futreal A, Gershenson DM, Greenberg RA, Huntsman DG, Ji JXY, Kohn EC, Iavarone C, Lengyel ER, Levine DA, Lord CJ, Lu Z, Mills GB, Modugno F, Nelson BH, Odunsi K, Pilsworth JA, Rottapel RK, Powell DJ, Shen L, Shih IM, Spriggs DR, Walton J, Zhang K, Zhang R, Zou L. Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 Jun 15; 125(12):1963-1972. PMID: 30835824.
      View in: PubMed
    8. Chapel DB, Lengyel E, Ritterhouse LL, Lastra RR. Interpretation of Mismatch Repair Protein Immunohistochemistry in Endometrial Carcinoma Should Consider Both Lynch Syndrome Screening and Immunotherapy Susceptibility: An Illustrative Case Report. Int J Gynecol Pathol. 2019 Feb 21. PMID: 30807370.
      View in: PubMed
    9. McGuire S, Kara B, Hart PC, Montag A, Wroblewski K, Fazal S, Huang XY, Lengyel E, Kenny HA. Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis. Gynecol Oncol. 2019 05; 153(2):405-415. PMID: 30797592.
      View in: PubMed
    10. Hart PC, Chiyoda T, Liu X, Weigert M, Curtis M, Chiang CY, Loth R, Lastra R, McGregor SM, Locasale JW, Lengyel E, Romero IL. SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 04; 17(4):870-881. PMID: 30655321.
      View in: PubMed
    11. Lee W, Ko SY, Mohamed MS, Kenny HA, Lengyel E, Naora H. Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum. J Exp Med. 2019 01 07; 216(1):176-194. PMID: 30567719.
      View in: PubMed
    12. Javellana M, Hoppenot C, Lengyel E. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer. Gynecol Oncol. 2019 02; 152(2):228-234. PMID: 30471899.
      View in: PubMed
    13. Loessner D, Rockstroh A, Shokoohmand A, Holzapfel BM, Wagner F, Baldwin J, Boxberg M, Schmalfeldt B, Lengyel E, Clements JA, Hutmacher DW. A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns. Biomaterials. 2019 01; 190-191:63-75. PMID: 30396040.
      View in: PubMed
    14. Coscia F, Lengyel E, Duraiswamy J, Ashcroft B, Bassani-Sternberg M, Wierer M, Johnson A, Wroblewski K, Montag A, Yamada SD, López-Méndez B, Nilsson J, Mund A, Mann M, Curtis M. Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer. Cell. 2018 09 20; 175(1):159-170.e16. PMID: 30241606.
      View in: PubMed
    15. Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis. Cell Metab. 2019 01 08; 29(1):141-155.e9. PMID: 30174305.
      View in: PubMed
    16. Liu J, Eckert MA, Harada BT, Liu SM, Lu Z, Yu K, Tienda SM, Chryplewicz A, Zhu AC, Yang Y, Huang JT, Chen SM, Xu ZG, Leng XH, Yu XC, Cao J, Zhang Z, Liu J, Lengyel E, He C. m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol. 2018 09; 20(9):1074-1083. PMID: 30154548.
      View in: PubMed
    17. Curtis M, Mukherjee A, Lengyel E. The Tumor Microenvironment Takes Center Stage in Ovarian Cancer Metastasis. Trends Cancer. 2018 08; 4(8):517-519. PMID: 30064659.
      View in: PubMed
    18. Matsuda T, Leisegang M, Park JH, Ren L, Kato T, Ikeda Y, Harada M, Kiyotani K, Lengyel E, Fleming GF, Nakamura Y. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Clin Cancer Res. 2018 11 01; 24(21):5357-5367. PMID: 29720506.
      View in: PubMed
    19. Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a Matter of Fat: The Crosstalk between Adipose Tissue and Tumors. Trends Cancer. 2018 05; 4(5):374-384. PMID: 29709261.
      View in: PubMed
    20. Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E. Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis. Oncogene. 2018 04; 37(17):2285-2301. PMID: 29398710.
      View in: PubMed
    21. Li G, Montgomery JE, Eckert MA, Chang JW, Tienda SM, Lengyel E, Moellering RE. An activity-dependent proximity ligation platform for spatially resolved quantification of active enzymes in single cells. Nat Commun. 2017 11 24; 8(1):1775. PMID: 29176560.
      View in: PubMed
    22. Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018 01; 148(1):204-212. PMID: 29128106.
      View in: PubMed
    23. Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF. High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer. Gynecol Oncol. 2017 07; 146(1):153-160. PMID: 28456378.
      View in: PubMed
    24. Chiyoda T, Hart PC, Eckert MA, McGregor SM, Lastra RR, Hamamoto R, Nakamura Y, Yamada SD, Olopade OI, Lengyel E, Romero IL. Loss of BRCA1 in the Cells of Origin of Ovarian Cancer Induces Glycolysis: A Window of Opportunity for Ovarian Cancer Chemoprevention. Cancer Prev Res (Phila). 2017 Apr; 10(4):255-266. PMID: 28264838.
      View in: PubMed
    25. Mukherjee A, Kenny HA, Lengyel E. Unsaturated Fatty Acids Maintain Cancer Cell Stemness. Cell Stem Cell. 2017 03 02; 20(3):291-292. PMID: 28257705.
      View in: PubMed
    26. Sundaram KM, Zhang Y, Mitra AK, Kouadio JK, Gwin K, Kossiakoff AA, Roman BB, Lengyel E, Piccirilli JA. Prolactin Receptor-Mediated Internalization of Imaging Agents Detects Epithelial Ovarian Cancer with Enhanced Sensitivity and Specificity. Cancer Res. 2017 04 01; 77(7):1684-1696. PMID: 28202518.
      View in: PubMed
    27. Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M. A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth. SLAS Discov. 2017 06; 22(5):494-506. PMID: 28346091.
      View in: PubMed
    28. Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers. Cell Metab. 2016 11 08; 24(5):728-739. PMID: 27746051.
      View in: PubMed
    29. Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351. PMID: 27856443.
      View in: PubMed
    30. Nakamura K, Sawada K, Kinose Y, Yoshimura A, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Morishige KI, Kurachi H, Lengyel E, Kimura T. Exosomes Promote Ovarian Cancer Cell Invasion through Transfer of CD44 to Peritoneal Mesothelial Cells. Mol Cancer Res. 2017 01; 15(1):78-92. PMID: 27758876.
      View in: PubMed
    31. Coscia F, Watters KM, Curtis M, Eckert MA, Chiang CY, Tyanova S, Montag A, Lastra RR, Lengyel E, Mann M. Integrative proteomic profiling of ovarian cancer cell lines reveals precursor cell associated proteins and functional status. Nat Commun. 2016 08 26; 7:12645. PMID: 27561551.
      View in: PubMed
    32. Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E. Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. Mol Cancer Ther. 2016 10; 15(10):2282-2293. PMID: 27466355.
      View in: PubMed
    33. Fehniger J, Thomas S, Lengyel E, Liao C, Tenney M, Oto A, Yamada SD. A prospective study evaluating diffusion weighted magnetic resonance imaging (DW-MRI) in the detection of peritoneal carcinomatosis in suspected gynecologic malignancies. Gynecol Oncol. 2016 07; 142(1):169-175. PMID: 27103176.
      View in: PubMed
    34. Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E. Erratum: Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2016 Feb 03; 7:10649. PMID: 26838815.
      View in: PubMed
    35. Peters PN, Schryver EM, Lengyel E, Kenny H. Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity. J Vis Exp. 2015 12 31; (106):e53541. PMID: 26780294.
      View in: PubMed
    36. Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ, Bast RC, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, Brenton JD, Chiappinelli KB, Martins FC, Coukos G, Drapkin R, Edmondson R, Fotopoulou C, Gabra H, Galon J, Gourley C, Heong V, Huntsman DG, Iwanicki M, Karlan BY, Kaye A, Lengyel E, Levine DA, Lu KH, McNeish IA, Menon U, Narod SA, Nelson BH, Nephew KP, Pharoah P, Powell DJ, Ramos P, Romero IL, Scott CL, Sood AK, Stronach EA, Balkwill FR. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015 Nov; 15(11):668-79. PMID: 26493647.
      View in: PubMed
    37. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS. Corrigendum: Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 Nov 19; 527(7578):398. PMID: 26503049.
      View in: PubMed
    38. Litchfield LM, Mukherjee A, Eckert MA, Johnson A, Mills KA, Pan S, Shridhar V, Lengyel E, Romero IL. Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer. Oncotarget. 2015 Sep 15; 6(27):23548-60. PMID: 26172303.
      View in: PubMed
    39. Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF, Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015 Sep; 138(3):656-62. PMID: 26115975.
      View in: PubMed
    40. Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S, Nones K, Cowin P, Alsop K, Bailey PJ, Kassahn KS, Newell F, Quinn MC, Kazakoff S, Quek K, Wilhelm-Benartzi C, Curry E, Leong HS. Whole-genome characterization of chemoresistant ovarian cancer. Nature. 2015 May 28; 521(7553):489-94. PMID: 26017449.
      View in: PubMed
    41. Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, Hashimoto K, Mabuchi S, Takahashi K, Kurachi H, Lengyel E, Kimura T. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget. 2015 May 10; 6(13):11342-56. PMID: 25839163.
      View in: PubMed
    42. Kohlhapp FJ, Mitra AK, Lengyel E, Peter ME. MicroRNAs as mediators and communicators between cancer cells and the tumor microenvironment. Oncogene. 2015 Nov 26; 34(48):5857-68. PMID: 25867073.
      View in: PubMed
    43. Hunn J, Tenney ME, Tergas AI, Bishop EA, Moore K, Watkin W, Kirschner C, Hurteau J, Rodriguez GC, Lengyel E, Lee NK, Yamada SD. Patterns and utility of routine surveillance in high grade endometrial cancer. Gynecol Oncol. 2015 Jun; 137(3):485-9. PMID: 25838164.
      View in: PubMed
    44. Mitra AK, Chiang CY, Tiwari P, Tomar S, Watters KM, Peter ME, Lengyel E. Microenvironment-induced downregulation of miR-193b drives ovarian cancer metastasis. Oncogene. 2015 Nov 26; 34(48):5923-32. PMID: 25798837.
      View in: PubMed
    45. Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E. Molecular pathways: trafficking of metabolic resources in the tumor microenvironment. Clin Cancer Res. 2015 Feb 15; 21(4):680-6. PMID: 25691772.
      View in: PubMed
    46. Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun. 2015 Feb 05; 6:6220. PMID: 25653139.
      View in: PubMed
    47. Febbraro T, Lengyel E, Romero IL. Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol. 2014 Dec; 135(3):614-21. PMID: 25455733.
      View in: PubMed
    48. Lengyel E, Litchfield LM, Mitra AK, Nieman KM, Mukherjee A, Zhang Y, Johnson A, Bradaric M, Lee W, Romero IL. Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol. 2015 Apr; 212(4):479.e1-479.e10. PMID: 25446664.
      View in: PubMed
    49. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, Ladanyi A, Penicka CV, George J, Matlin K, Montag A, Wroblewski K, Yamada SD, Mazar AP, Bowtell D, Lengyel E. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014 Oct; 124(10):4614-28. PMID: 25202979.
      View in: PubMed
    50. King ML, Lindberg ME, Stodden GR, Okuda H, Ebers SD, Johnson A, Montag A, Lengyel E, MacLean Ii JA, Hayashi K. WNT7A/ß-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015 Jun; 34(26):3452-62. PMID: 25174399.
      View in: PubMed
    51. Habis M, Wroblewski K, Bradaric M, Ismail N, Yamada SD, Litchfield L, Lengyel E, Romero IL. Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One. 2014; 9(8):e104521. PMID: 25118694.
      View in: PubMed
    52. White EA, Kenny HA, Lengyel E. Three-dimensional modeling of ovarian cancer. Adv Drug Deliv Rev. 2014 Dec 15; 79-80:184-92. PMID: 25034878.
      View in: PubMed
    53. Ko SY, Ladanyi A, Lengyel E, Naora H. Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol. 2014 Jan; 184(1):271-81. PMID: 24332016.
      View in: PubMed
    54. Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel E. Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy. Mol Cancer Ther. 2013 Dec; 12(12):2628-39. PMID: 24061648.
      View in: PubMed
    55. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS. Epithelial ovarian cancer experimental models. Oncogene. 2014 Jul 10; 33(28):3619-33. PMID: 23934194.
      View in: PubMed
    56. Landen CN, Lengyel E. Summary of the 2013 American Association for Cancer Research (AACR) Annual Meeting. Gynecol Oncol. 2013 Jul; 130(1):6-8. PMID: 23926600.
      View in: PubMed
    57. Ohyagi-Hara C, Sawada K, Kamiura S, Tomita Y, Isobe A, Hashimoto K, Kinose Y, Mabuchi S, Hisamatsu T, Takahashi T, Kumasawa K, Nagata S, Morishige K, Lengyel E, Kurachi H, Kimura T. miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin a5 expression. Am J Pathol. 2013 May; 182(5):1876-89. PMID: 23499550.
      View in: PubMed
    58. Nieman KM, Romero IL, Van Houten B, Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013 Oct; 1831(10):1533-41. PMID: 23500888.
      View in: PubMed
    59. Lengyel E, Fleming S, McEwen KA, Montag A, Temkin SM. Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol. 2013 Apr; 129(1):120-3. PMID: 23237768.
      View in: PubMed
    60. Mitra AK, Zillhardt M, Hua Y, Tiwari P, Murmann AE, Peter ME, Lengyel E. MicroRNAs reprogram normal fibroblasts into cancer-associated fibroblasts in ovarian cancer. Cancer Discov. 2012 Dec; 2(12):1100-8. PMID: 23171795.
      View in: PubMed
    61. Hunn J, Tenney M, Bishop E, Moore K, Tergas A, Lengyel E, Lee N, Yamada S. Utility of routine surveillance methods in detecting recurrence in high grade endometrial cancer patients. Gynecol Oncol. 2012 Oct; 127(1 Suppl):S5-6. PMID: 24989588.
      View in: PubMed
    62. Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012 Oct; 122(10):3603-17. PMID: 22945634.
      View in: PubMed
    63. Tergas AI, Buell-Gutbrod R, Gwin K, Kocherginsky M, Temkin SM, Fefferman A, Lengyel E, Yamada SD. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure. Gynecol Oncol. 2012 Nov; 127(2):316-20. PMID: 22835717.
      View in: PubMed
    64. Romero IL, McCormick A, McEwen KA, Park S, Karrison T, Yamada SD, Pannain S, Lengyel E. Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol. 2012 Jan; 119(1):61-7. PMID: 22183212.
      View in: PubMed
    65. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011 Oct 30; 17(11):1498-503. PMID: 22037646.
      View in: PubMed
    66. Romero IL, Lee W, Mitra AK, Gordon IO, Zhao Y, Leonhardt P, Penicka CV, Mui KL, Krausz TN, Greene GL, Lengyel E. The effects of 17ß-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol. 2012 Jan; 124(1):134-41. PMID: 21996264.
      View in: PubMed
    67. Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011 Sep 23; 11(10):719-25. PMID: 21941283.
      View in: PubMed
    68. Boyerinas B, Park SM, Murmann AE, Gwin K, Montag AG, Zillhardt M, Hua YJ, Lengyel E, Peter ME. Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer. 2012 Apr 15; 130(8):1787-97. PMID: 21618519.
      View in: PubMed
    69. Lengyel E, Nicklas M, Jeevan HS, Geibel C, Steglich F. Pressure tuning of the interplay of magnetism and superconductivity in CeCu2Si2. Phys Rev Lett. 2011 Jul 29; 107(5):057001. PMID: 21867090.
      View in: PubMed
    70. Kenny HA, Nieman KM, Mitra AK, Lengyel E. The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov. 2011 Jul; 1(2):100-2. PMID: 22013555.
      View in: PubMed
    71. Buell-Gutbrod R, Ivanovic M, Montag A, Lengyel E, Fadare O, Gwin K. FOXL2 and SOX9 distinguish the lineage of the sex cord-stromal cells in gonadoblastomas. Pediatr Dev Pathol. 2011 Sep-Oct; 14(5):391-5. PMID: 21682576.
      View in: PubMed
    72. Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E. Foretinib (GSK1363089), an orally available multikinase inhibitor of c-Met and VEGFR-2, blocks proliferation, induces anoikis, and impairs ovarian cancer metastasis. Clin Cancer Res. 2011 Jun 15; 17(12):4042-51. PMID: 21551255.
      View in: PubMed
    73. Bell-McGuinn KM, Matthews CM, Ho SN, Barve M, Gilbert L, Penson RT, Lengyel E, Palaparthy R, Gilder K, Vassos A, McAuliffe W, Weymer S, Barton J, Schilder RJ. A phase II, single-arm study of the anti-a5ß1 integrin antibody volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary peritoneal cancer. Gynecol Oncol. 2011 May 01; 121(2):273-9. PMID: 21276608.
      View in: PubMed
    74. Temkin SM, Turner JR, Lengyel ER. Acute inflammatory reaction following placement of sodium hyaluronate-carboxymethylcellulose barrier in a young woman undergoing gynecologic surgery: a case report. J Reprod Med. 2011 Jan-Feb; 56(1-2):71-4. PMID: 21366131.
      View in: PubMed
    75. Bishop EA, Lengyel ER, Yamada SD, Montag A, Temkin SM. The expression of hepatocyte growth factor (HGF) and c-Met in uterine serous carcinoma. Gynecol Oncol. 2011 Apr; 121(1):218-23. PMID: 21168200.
      View in: PubMed
    76. Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E. Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis. Clin Cancer Res. 2011 Feb 01; 17(3):459-71. PMID: 21149615.
      View in: PubMed
    77. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and a(5)ß(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene. 2011 Mar 31; 30(13):1566-76. PMID: 21119598.
      View in: PubMed
    78. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010 Sep; 177(3):1053-64. PMID: 20651229.
      View in: PubMed
    79. Chen L, Park SM, Tumanov AV, Hau A, Sawada K, Feig C, Turner JR, Fu YX, Romero IL, Lengyel E, Peter ME. CD95 promotes tumour growth. Nature. 2010 May 27; 465(7297):492-6. PMID: 20505730.
      View in: PubMed
    80. Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia. 2010 Jan; 12(1):1-10. PMID: 20072648.
      View in: PubMed
    81. Ko SY, Lengyel E, Naora H. The Müllerian HOXA10 gene promotes growth of ovarian surface epithelial cells by stimulating epithelial-stromal interactions. Mol Cell Endocrinol. 2010 Apr 12; 317(1-2):112-9. PMID: 20036708.
      View in: PubMed
    82. Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel E. {beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer. Am J Pathol. 2009 Nov; 175(5):2184-96. PMID: 19808644.
      View in: PubMed
    83. Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM, Krausz TN, Kim HH, Gilliam ML, Lengyel E. Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila). 2009 Sep; 2(9):792-9. PMID: 19737983.
      View in: PubMed
    84. Banz C, Ungethuem U, Kuban RJ, Diedrich K, Lengyel E, Hornung D. The molecular signature of endometriosis-associated endometrioid ovarian cancer differs significantly from endometriosis-independent endometrioid ovarian cancer. Fertil Steril. 2010 Sep; 94(4):1212-7. PMID: 19643405.
      View in: PubMed
    85. Deplazes J, Fuchs M, Rauser S, Genth H, Lengyel E, Busch R, Luber B. Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum Mol Genet. 2009 Oct 01; 18(19):3632-44. PMID: 19584084.
      View in: PubMed
    86. Arimoto-Ishida E, Sakata M, Sawada K, Nakayama M, Nishimoto F, Mabuchi S, Takeda T, Yamamoto T, Isobe A, Okamoto Y, Lengyel E, Suehara N, Morishige K, Kimura T. Up-regulation of alpha5-integrin by E-cadherin loss in hypoxia and its key role in the migration of extravillous trophoblast cells during early implantation. Endocrinology. 2009 Sep; 150(9):4306-15. PMID: 19497979.
      View in: PubMed
    87. Kenny HA, Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis. Cell Cycle. 2009 Mar 01; 8(5):683-8. PMID: 19221481.
      View in: PubMed
    88. Knudsen BS, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, Berghuis B, Daugherty J, Grabinski T, Toro J, Giambernardi T, Skinner RS, Gross M, Hudson E, Kort E, Lengyel E, Ventura A, West RA, Xie Q, Hay R, Vande Woude G, Cao B. A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings. Appl Immunohistochem Mol Morphol. 2009 Jan; 17(1):57-67. PMID: 18815565.
      View in: PubMed
    89. Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel E. Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis. Cancer Treat Res. 2009; 149:335-51. PMID: 19763444.
      View in: PubMed
    90. Terplan M, Temkin S, Tergas A, Lengyel E. Does equal treatment yield equal outcomes? The impact of race on survival in epithelial ovarian cancer. Gynecol Oncol. 2008 Nov; 111(2):173-8. PMID: 18823649.
      View in: PubMed
    91. Lindemann K, Harbeck N, Lengyel E, Resau JH. A special key for unlocking the door to targeted therapies of breast cancer. ScientificWorldJournal. 2008 Sep 21; 8:905-8. PMID: 18836657.
      View in: PubMed
    92. Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol. 2008 Dec; 111(3):537-9. PMID: 18554701.
      View in: PubMed
    93. Temkin SM, Lengyel E, Tergas A, Terplan M. Ovarian cancer treatment in black and white women: A comparison of clinico-pathologic factors and outcome. J Clin Oncol. 2008 May 20; 26(15_suppl):16531. PMID: 27948864.
      View in: PubMed
    94. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008 Apr 01; 68(7):2329-39. PMID: 18381440.
      View in: PubMed
    95. Park SM, Gaur AB, Lengyel E, Peter ME. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008 Apr 01; 22(7):894-907. PMID: 18381893.
      View in: PubMed
    96. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008 Apr; 118(4):1367-79. PMID: 18340378.
      View in: PubMed
    97. Radjabi AR, Sawada K, Jagadeeswaran S, Eichbichler A, Kenny HA, Montag A, Bruno K, Lengyel E. Thrombin induces tumor invasion through the induction and association of matrix metalloproteinase-9 and beta1-integrin on the cell surface. J Biol Chem. 2008 Feb 01; 283(5):2822-34. PMID: 18048360.
      View in: PubMed
    98. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer. 2007 Oct 01; 121(7):1463-72. PMID: 17546601.
      View in: PubMed
    99. Park SM, Shell S, Radjabi AR, Schickel R, Feig C, Boyerinas B, Dinulescu DM, Lengyel E, Peter ME. Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle. 2007 Nov 01; 6(21):2585-90. PMID: 17957144.
      View in: PubMed
    100. Lindemann K, Resau J, Nährig J, Kort E, Leeser B, Annecke K, Welk A, Schäfer J, Vande Woude GF, Lengyel E, Harbeck N. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology. 2007 Jul; 51(1):54-62. PMID: 17593080.
      View in: PubMed
    101. Shell S, Park SM, Radjabi AR, Schickel R, Kistner EO, Jewell DA, Feig C, Lengyel E, Peter ME. Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A. 2007 Jul 03; 104(27):11400-5. PMID: 17600087.
      View in: PubMed
    102. Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H. Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer. Mol Cancer Res. 2007 May; 5(5):485-96. PMID: 17510314.
      View in: PubMed
    103. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, Turkyilmaz MA, Salgia R, Yamada SD, Vande Woude GF, Tretiakova MS, Lengyel E. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res. 2007 Feb 15; 67(4):1670-9. PMID: 17308108.
      View in: PubMed
    104. Lengyel E, Sawada K, Salgia R. Tyrosine kinase mutations in human cancer. Curr Mol Med. 2007 Feb; 7(1):77-84. PMID: 17311534.
      View in: PubMed
    105. Adams SF, Hickson JA, Hutto JY, Montag AG, Lengyel E, Yamada SD. PDGFR-alpha as a potential therapeutic target in uterine sarcomas. Gynecol Oncol. 2007 Mar; 104(3):524-8. PMID: 17049587.
      View in: PubMed
    106. Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006 Dec 01; 66(5):1356-65. PMID: 16757127.
      View in: PubMed
    107. Schewe DM, Biller T, Maurer G, Asangani IA, Leupold JH, Lengyel ER, Post S, Allgayer H. Combination analysis of activator protein-1 family members, Sp1 and an activator protein-2alpha-related factor binding to different regions of the urokinase receptor gene in resected colorectal cancers. Clin Cancer Res. 2005 Dec 15; 11(24 Pt 1):8538-48. PMID: 16361535.
      View in: PubMed
    108. Szavcsur P, Godény M, Bajzik G, Lengyel E, Repa I, Trón L, Boér A, Vincze B, Póti Z, Szabolcs I, Esik O. Angiography-proven liver metastases explain low efficacy of lymph node dissections in medullary thyroid cancer patients. Eur J Surg Oncol. 2005 Mar; 31(2):183-90. PMID: 15698736.
      View in: PubMed
    109. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005 Feb 10; 113(4):678-82. PMID: 15455388.
      View in: PubMed
    110. Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene. 2004 Dec 16; 23(58):9369-80. PMID: 15516977.
      View in: PubMed
    111. Kugler MC, Gerhard M, Schnelzer A, Borzym K, Reinhardt R, Schmitt M, Lengyel E. Isolation and characterization of Rac1 pseudogenes (psi1Rac1-psi4Rac1) in the human genome. Gene. 2004 Oct 27; 341:189-97. PMID: 15474301.
      View in: PubMed
    112. Chen LM, Lengyel ER, Bethan Powell C. Single-agent pulse dactinomycin has only modest activity for methotrexate-resistant gestational trophoblastic neoplasia. Gynecol Oncol. 2004 Jul; 94(1):204-7. PMID: 15262143.
      View in: PubMed
    113. Schewe DM, Leupold JH, Boyd DD, Lengyel ER, Wang H, Gruetzner KU, Schildberg FW, Jauch KW, Allgayer H. Tumor-specific transcription factor binding to an activator protein-2/Sp1 element of the urokinase-type plasminogen activator receptor promoter in a first large series of resected gastrointestinal cancers. Clin Cancer Res. 2003 Jun; 9(6):2267-76. PMID: 12796395.
      View in: PubMed
    114. Besta F, Massberg S, Brand K, Müller E, Page S, Grüner S, Lorenz M, Sadoul K, Kolanus W, Lengyel E, Gawaz M. Role of beta(3)-endonexin in the regulation of NF-kappaB-dependent expression of urokinase-type plasminogen activator receptor. J Cell Sci. 2002 Oct 15; 115(Pt 20):3879-88. PMID: 12244126.
      View in: PubMed
    115. Schmalfeldt B, Prechtel D, Härting K, Späthe K, Rutke S, Konik E, Fridman R, Berger U, Schmitt M, Kuhn W, Lengyel E. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res. 2001 Aug; 7(8):2396-404. PMID: 11489818.
      View in: PubMed
    116. Lengyel E, Schmalfeldt B, Konik E, Späthe K, Härting K, Fenn A, Berger U, Fridman R, Schmitt M, Prechtel D, Kuhn W. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol. 2001 Aug; 82(2):291-8. PMID: 11531282.
      View in: PubMed
    117. Gerhard M, Neumayer N, Presecan-Siedel E, Zanner R, Lengyel E, Cramer T, Höcker M, Prinz C. Gastrin induces expression and promoter activity of the vesicular monoamine transporter subtype 2. Endocrinology. 2001 Aug; 142(8):3663-72. PMID: 11459816.
      View in: PubMed
    118. Gerhard M, Neumayer N, Presecan-Siedel E, Zanner R, Lengyel E, Cramer T, Ho Cker M, Prinz C. Gastrin Induces Expression and Promoter Activity of the Vesicular Monoamine Transporter Subtype 2. Endocrinology. 2001 Aug 01; 142(8):3663-3672. PMID: 28201526.
      View in: PubMed
    119. Hapke S, Kessler H, Arroyo de Prada N, Benge A, Schmitt M, Lengyel E, Reuning U. Integrin alpha(v)beta(3)/vitronectin interaction affects expression of the urokinase system in human ovarian cancer cells. J Biol Chem. 2001 Jul 13; 276(28):26340-8. PMID: 11331280.
      View in: PubMed
    120. Hapke S, Gawaz M, Dehne K, Köhler J, Marshall JF, Graeff H, Schmitt M, Reuning U, Lengyel E. beta(3)A-integrin downregulates the urokinase-type plasminogen activator receptor (u-PAR) through a PEA3/ets transcriptional silencing element in the u-PAR promoter. Mol Cell Biol. 2001 Mar; 21(6):2118-32. PMID: 11238946.
      View in: PubMed
    121. Iesalnieks I, Rentsch M, Lengyel E, Mirwald T, Jauch K, Beham A. JNK and p38MAPK are activated during graft reperfusion and not during cold storage in rat liver transplantation. Transplant Proc. 2001 Feb-Mar; 33(1-2):931-2. PMID: 11267133.
      View in: PubMed
    122. Lengyel E, Ried S, Heiss MM, Jäger C, Schmitt M, Allgayer H. Ras regulation of urokinase-type plasminogen activator. Methods Enzymol. 2001; 333:105-16. PMID: 11400328.
      View in: PubMed
    123. Dickfeld T, Lengyel E, May AE, Massberg S, Brand K, Page S, Thielen C, Langenbrink K, Gawaz M. Transient interaction of activated platelets with endothelial cells induces expression of monocyte-chemoattractant protein-1 via a p38 mitogen-activated protein kinase mediated pathway. Implications for atherogenesis. Cardiovasc Res. 2001 Jan; 49(1):189-99. PMID: 11121811.
      View in: PubMed
    124. Muehlenweg B, Schnelzer A, Türkmen B, Lengyel E, Reuning U, Graeff H, Schmitt M, Magdolen V. RFLP Molecular Analysis of the Urokinase-Type Plasminogen Activator Gene. Methods Mol Med. 2001; 39:299-306. PMID: 21340784.
      View in: PubMed
    125. Hannke-Lohmann A, Pildner von Steinburg S, Dehne K, Benard V, Kolben M, Schmitt M, Lengyel E. Downregulation of a mitogen-activated protein kinase signaling pathway in the placentas of women with preeclampsia. Obstet Gynecol. 2000 Oct; 96(4):582-7. PMID: 11004363.
      View in: PubMed
    126. Schnelzer A, Prechtel D, Knaus U, Dehne K, Gerhard M, Graeff H, Harbeck N, Schmitt M, Lengyel E. Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene. 2000 Jun 15; 19(26):3013-20. PMID: 10871853.
      View in: PubMed
    127. Marschall C, Lengyel E, Nobutoh T, Braungart E, Douwes K, Simon A, Magdolen V, Reuning U, Degitz K. UVB increases urokinase-type plasminogen activator receptor (uPAR) expression. J Invest Dermatol. 1999 Jul; 113(1):69-76. PMID: 10417621.
      View in: PubMed
    128. Ried S, Jäger C, Jeffers M, Vande Woude GF, Graeff H, Schmitt M, Lengyel E. Activation mechanisms of the urokinase-type plasminogen activator promoter by hepatocyte growth factor/scatter factor. J Biol Chem. 1999 Jun 04; 274(23):16377-86. PMID: 10347197.
      View in: PubMed
    129. Schaller G, Fuchs I, Ebert A, Gstettenbauer M, Herbst H, Lengyel E. [The clinical importance of keratin 18 in breast cancer]. Zentralbl Gynakol. 1999; 121(3):126-30. PMID: 10209854.
      View in: PubMed
    130. Jacob K, Wach F, Holzapfel U, Hein R, Lengyel E, Buettner R, Bosserhoff AK. In vitro modulation of human melanoma cell invasion and proliferation by all-trans-retinoic acid. Melanoma Res. 1998 Jun; 8(3):211-9. PMID: 9664142.
      View in: PubMed
    131. Lengyel E, Somogyi A, Molnár T, Tóth E, Remenár E, Skriba Z, Esik O. [Juvenile aneuploid papillary cancer of the thyroid with pulmonary metastasis]. Orv Hetil. 1998 Mar 22; 139(12):687-90. PMID: 9555165.
      View in: PubMed
    132. Lengyel E, Wang H, Gum R, Simon C, Wang Y, Boyd D. Elevated urokinase-type plasminogen activator receptor expression in a colon cancer cell line is due to a constitutively activated extracellular signal-regulated kinase-1-dependent signaling cascade. Oncogene. 1997 May 29; 14(21):2563-73. PMID: 9191056.
      View in: PubMed
    133. Gum R, Wang H, Lengyel E, Juarez J, Boyd D. Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene. 1997 Mar 27; 14(12):1481-93. PMID: 9136992.
      View in: PubMed
    134. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H, Lengyel E. Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res. 1996 Nov; 2(11):1879-85. PMID: 9816144.
      View in: PubMed
    135. Lengyel E, Wang H, Stepp E, Juarez J, Wang Y, Doe W, Pfarr CM, Boyd D. Requirement of an upstream AP-1 motif for the constitutive and phorbol ester-inducible expression of the urokinase-type plasminogen activator receptor gene. J Biol Chem. 1996 Sep 20; 271(38):23176-84. PMID: 8798512.
      View in: PubMed
    136. Lengyel E, Gum R, Stepp E, Juarez J, Wang H, Boyd D. Regulation of urokinase-type plasminogen activator expression by an ERK1-dependent signaling pathway in a squamous cell carcinoma cell line. J Cell Biochem. 1996 Jun 01; 61(3):430-43. PMID: 8761947.
      View in: PubMed
    137. Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D. Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem. 1996 May 03; 271(18):10672-80. PMID: 8631874.
      View in: PubMed
    138. Lengyel E, Stepp E, Gum R, Boyd D. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-ras. J Biol Chem. 1995 Sep 29; 270(39):23007-12. PMID: 7559439.
      View in: PubMed
    139. Lengyel E, Klostergaard J, Boyd D. Stimulation of urokinase expression by TNF-alpha requires the activation of binding sites for the AP-1 and PEA3 transcription factors. Biochim Biophys Acta. 1995 Jul 20; 1268(1):65-72. PMID: 7626664.
      View in: PubMed
    140. Gum R, Wang SW, Lengyel E, Yu D, Hung MC, Juarez J, Boyd D. Up-regulation of urokinase-type plasminogen activator expression by the HER2/neu proto-oncogene. Anticancer Res. 1995 Jul-Aug; 15(4):1167-72. PMID: 7653995.
      View in: PubMed
    141. Lengyel E, Gum R, Juarez J, Clayman G, Seiki M, Sato H, Boyd D. Induction of M(r) 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts. Cancer Res. 1995 Feb 15; 55(4):963-7. PMID: 7850814.
      View in: PubMed
    142. Schaller G, Lengyel E, Pantel K, Hardt W, Mischke D. Keratin expression reveals mosaic differentiation in vaginal epithelium. Am J Obstet Gynecol. 1993 Dec; 169(6):1603-7. PMID: 7505531.
      View in: PubMed
    Lengyel's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _